Newport Pharmaceuticals Dublin:
Source: Bioaccelerate, Inc.
Newport Pharmaceuticals Ltd. Announces Update on Co-Development Program For
Isoprinosine DUBLIN, Ireland, Oct. 31, 2005 (PRIMEZONE) -- Newport
Pharmaceuticals Ltd (NPL), a privately owned company focusing on
immunological disorders, commented today on its phase II clinical
development program for lead product Isoprinosine(r) (Inosine Acetoben
Dimepranol) (IAD) for the treatment of chronic fatigue syndrome (CFS) in the
"The unmet therapeutic need in CFS is well recognised," said James O'Daly,
Managing Director of Newport. "According to the American Chronic Fatigue and
Immune Dysfunction Society (CFIDS), there may be 800,000 people in the U.S.
suffering from the illness. One of the key competitive advantages at this
stage of the development of Isoprinosine is the proven safety record in
licensed indications in many countries. Secondly, there is an increasing
level of awareness of Isoprinosine as a potential treatment for CFS within
the medical and patient communities. This level of awareness is particularly
high amongst U.S. CFS doctors."
Newport's co-development partner, Amilar Pharmaceuticals, is a speciality
pharmaceutical company with development stage compounds in women's health.
Amilar is a wholly owned subsidiary of Bioaccelerate Holdings Inc.
"We believe Isoprinosine has significant commercial potential in the
treatment of chronic fatigue syndrome, and we are excited to be working with
Newport Pharmaceuticals to advance this program through late-stage clinical
development and commercialization," stated Christopher O'Toole, Head of
Specialty Pharmaceuticals for Bioaccelerate.
Newport has been pursuing a program for the development of Isoprinosine(r)
as a treatment for CFS since 1999. The company conducted its first Phase II
trial in Canada and the results are summarised in Diaz-Mitoma, F et al.
'Clinical improvement in chronic fatigue syndrome is associated with
enhanced natural killer cell-mediated cytotoxicity: the results of a pilot
study with Isoprinosine(r)' JCFS 2003.
About Newport Pharmaceuticals Ltd.
Newport Pharmaceuticals Ltd was established in 1996 to focus on the
pharmaceutical interests of the Newport holding company, following the
acquisition of Newport Synthesis from the American parent Systemed Inc, in
March 1995. Newport continues to grow as a profitable pharmaceutical company
focussed on products for the treatment of infectious diseases, immunological
diseases and related conditions. IAD (Isoprinosine/Imunovir) is a synthetic
purine derivative. It is an immunopharmacologic agent with both
immunomodulatory and antiviral properties. IAD has been licensed since 1971
for the treatment of cell mediated immune deficiencies associated with
various viral infections. It has been on the market for over 30 years and is
currently registered in 43 countries world wide for a variety of
Bioaccelerate Holdings Inc. (OTCBB:BACL) is a pharmaceutical development
organization ("PDO") that seeks to acquire, develop and commercialize novel
pharmaceutical compounds in an efficient, cost-effective way. Bioaccelerate
uses its broad network of academic, industry and capital market
relationships to expedite drug development and raise capital to create and
fund its subsidiary companies, which are organized by vertical portfolios in
five therapeutic areas: oncology, specialty pharmaceuticals, central nervous
system disorders (CNS), cardiovascular disease and anti-infectives.
Bioaccelerate conducts its business directly and through its subsidiaries.
The company holds majority equity interests in 10 biopharmaceutical
companies, three of which are public, and holds minority interests in four
biopharmaceutical companies, two of which are public. The company also holds
a minority equity interest in a public nanotechnology company.
Bioaccelerate's strategy relies on its development network for research,
clinical development and project management to guide early-stage compounds
from the discovery process through to Phase II/III development where
incremental value can be created. Bioaccelerate Holdings is listed on the
Over-The-Counter Bulletin Board under the symbol "BACL." For more
information on Bioaccelerate, visit the company's website at
Bioaccelerate Safe Harbor Statement
Certain statements contained herein are "forward-looking" statements (as
such term is defined in the Private Securities Litigation Reform Act of
1995). Because these statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Specifically, factors that could cause actual
results to differ materially from those expressed or implied by such
forward-looking statements include, but are not limited to: risks associated
with pre-clinical and clinical developments in the biopharmaceutical
industry in general and in Bioaccelerate's compounds under development in
particular; the potential failure of Bioaccelerate's compounds under
development to prove safe and effective for treatment of disease;
uncertainties inherent in the early stage of Bioaccelerate's compounds under
development; failure to successfully implement or complete clinical trials;
failure to receive marketing clearance from regulatory agencies for our
compounds under development; acquisitions, divestitures, mergers, licenses
or strategic initiatives that change Bioaccelerate's business, structure or
projections; the development of competing products; uncertainties related to
Bioaccelerate's dependence on third parties and partners; and those risks
described in the filings with the SEC, all of which are under
Bioaccelerate's prior name Mobile Design Concepts, Inc. Bioaccelerate
disclaims any obligation to update these forward-looking statements.
Bioaccelerate Holdings Inc.
Newport Pharmaceuticals Ltd
+353 (1) 8903011
<<< Back to Snippets Index